Suchergebnisse - "Verzoni, Elena"

PubPharm (208)

1

Gender Difference in sidE eFfects of ImmuNotherapy : a possible clue to optimize cancEr tReatment (G-DEFINER): study protocol of an observational prospective multicenter study

enthalten in: Acta oncologica (Stockholm, Sweden) | 2024

von Miceli, R. | Eriksson, H. | Lo Russo, G. | +16

2

Avelumab Plus Intermittent Axitinib in Previously Untreated Patients with Metastatic Renal Cell Carcinoma. The Tide-A Phase 2 Study

enthalten in: European urology | 2024

von Iacovelli, R. | Ciccarese, C. | Buti, S. | +22

3

Real World Analysis of Peritoneal Metastasis From Renal Cell Carcinoma. Meet-Uro27

enthalten in: Clinical genitourinary cancer | 2024

von Stellato, M. | Buti, S. | Maruzzo, M. | +19

4

Long-Term Survival in Patients With Relapsed/Refractory Advanced Renal Cell Carcinoma Treated With Tivozanib : Analysis of the Phase III TIVO-3 Trial

enthalten in: The oncologist | 2024

von Beckermann, K. | Asnis-Alibozek, A. | Atkins, M. | +8

5

CaboCombo : a prospective, phase IV study of first-line cabozantinib + nivolumab for advanced renal cell carcinoma

enthalten in: Future oncology (London, England) | 2024

von Barthélémy, P. | Dutailly, P. | Qvick, B. | +2

6

Characteristics and outcomes of immunotherapy-related liver injury in patients with hepatocellular carcinoma versus other advanced solid tumours

enthalten in: Journal of hepatology | 2024

von Celsa, C. | Cabibbo, G. | Fulgenzi, C. | +69

7

Impact of Prior Cytoreductive Nephrectomy on Efficacy in Patients with Synchronous Metastatic Renal Cell Carcinoma Treated with Avelumab plus Axitinib or Sunitinib : Post Hoc Analysis from the JAVELIN Renal 101 Phase 3 Trial

enthalten in: European urology | 2024

von Grimm, M. | Oya, M. | Choueiri, T. | +11

8

A phase II study evaluating the efficacy of enzalutamide and the role of liquid biopsy for evaluation of ARv7 in mCRPC patients with measurable metastases including visceral disease (Excalibur study)

enthalten in: Therapeutic advances in medical oncology | 2024

von Sepe, P. | Procopio, G. | Pircher, C. | +16

9

Hematological Toxicity of PARP Inhibitors in Metastatic Prostate Cancer Patients with Mutations of BRCA or HRR Genes : A Systematic Review and Safety Meta-analysis

enthalten in: Targeted oncology | 2024

von Maiorano, B. | De Giorgi, U. | Verzoni, E. | +5

ErratumIn: Target Oncol. 2023 Dec 9;:. - PMID 38070004

10

Correction to : Hematological Toxicity of PARP Inhibitors in Metastatic Prostate Cancer Patients with Mutations of BRCA or HRR Genes: A Systematic Review and Safety Meta-analysis

enthalten in: Targeted oncology | 2024

von Maiorano, B. | De Giorgi, U. | Verzoni, E. | +5

ErratumFor: Target Oncol. 2024 Jan;19(1):1-11. - PMID 37993604

1
2
3
4
5
6
7
8
9
10
11
Nächster »
[21]